SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-055235
Filing Date
2021-11-08
Accepted
2021-11-08 16:01:16
Documents
68
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q apls-10q_20210930.htm   iXBRL 10-Q 3475631
2 EX-31.1 apls-ex311_9.htm EX-31.1 18440
3 EX-31.2 apls-ex312_6.htm EX-31.2 17555
4 EX-32.1 apls-ex321_8.htm EX-32.1 8566
5 EX-32.2 apls-ex322_7.htm EX-32.2 8580
  Complete submission text file 0001564590-21-055235.txt   9924332

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA apls-20210930.xsd EX-101.SCH 64770
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE apls-20210930_cal.xml EX-101.CAL 47803
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE apls-20210930_def.xml EX-101.DEF 207947
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20210930_lab.xml EX-101.LAB 440173
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20210930_pre.xml EX-101.PRE 346678
11 EXTRACTED XBRL INSTANCE DOCUMENT apls-10q_20210930_htm.xml XML 1600250
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38276 | Film No.: 211387819
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences